Table 5 Medications in women with HFrEF and HFpEF subgroups
| Â | HFrEF, n = 73 | HFpEF, n = 45 | P value |
|---|---|---|---|
Thazides | 5 (6.85%) | 3 (6.7%) | 0.969 |
Loop diuretics | 40 (54.8%) | 28 (62.22%) | 0.428 |
Nitrates | 39 (53.4%) | 28 (62.22%) | 0.349 |
Warfarin | 17 (23.3%) | 14 (31.11%) | 0.348 |
Clopidogril | 41 (56.2%) | 17 (37.8%) | 0.052 |
CCB | 2 (2.74%) | 6 (13.33%) | 0.026 |
Amiodarone | 10 (13.7%) | 7 (15.6%) | 0.780 |
Unfractunated heparin | 19 (26.02%) | 15 (33.33%) | 0.395 |
LMWH | 52 (71.23%) | 27 (60%) | 0.208 |
Lytic therapy | 24 (32.88%) | 8 (17.8%) | 0.073 |
Aldosterone antagonist | 32 (43.8%) | 18 (40%) | 0.682 |
Digixon | 19 (26.03%) | 13 (28.9%) | 0.734 |
PPIH blockers | 55 (75.34%) | 42 (93.3%) | 0.013 |
Warfarin A | 10 (13.7%) | 12 (26.7%) | 0.079 |
ASA | 60 (82.2%) | 28 (62.22%) | 0.016 |
Beta-blockers | 27 (37%) | 18 (40%) | 0.743 |
ACEI | 38 (52.1%) | 22 (49%) | 0.738 |
ARBs | 8 (11%) | 10 (22.22%) | 0.098 |
Statin | 58 (79.5%) | 32 (71.1%) | 0.301 |